Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CCKBR | P32239 | 1/20 | 0.39 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.38 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.38 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | ANPEP | P15144 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | RBP4 | P02753 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7828421 | 1.00 | ATM (0.42) | ATMMEN1KMT2APOLBCCKBR | |
| Water SCHEMBL8600954 | 0.99 | ATM (0.42) | ATMMEN1KMT2APOLBCCKBR | |
| SCHEMBL9327248 | 0.90 | MAPT (0.46) | ATMMEN1KMT2APOLBNAALAD2 | |
| SCHEMBL11431737 | 0.90 | MAPT (0.46) | ATMMEN1KMT2APOLBNAALAD2 | |
| SCHEMBL9567734 | 0.90 | MAPT (0.46) | ATMMEN1KMT2APOLBNAALAD2 | |
| SCHEMBL10543158 | 0.90 | POLB (0.40) | MEN1KMT2APOLBCCKBRMAPT | |
| SCHEMBL9814590 | 0.90 | MEN1 (0.38) | MEN1KMT2APOLBCCKBRMAPT | |
| SCHEMBL8600205 | 0.90 | POLB (0.40) | MEN1KMT2APOLBCCKBRMAPT | |
| SCHEMBL10372875 | 0.90 | GPR88 (0.39) | MEN1KMT2APOLBCCKBRMAPT | |
| SCHEMBL11282995 | 0.90 | ATM (0.42) | ATMMEN1KMT2ACCKBRNAALAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0820999-A1 | A process for the preparation of penicillins | Ribbon S.r.L. (IT) | 1998-01-28 | — | — | EP | claimed |
| US-4837317-A | Process for the preparation of 6-[D(-)alpha-(4-ethyl-2,3-dioxopiperazin-1-ylcarbonylamino)-alpha-phenylacetamido]-penicillanic acid and intermediates useful in this process | BIOCHIMICA OPOS S.P.A. (IT) | 1989-06-06 | — | — | US | claimed |
| US-12173018-B2 | Penicillin-binding protein inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2024-12-24 | — | — | US | disclosed |
| US-11332485-B2 | Penicillin-binding protein inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2022-05-17 | — | — | US | disclosed |
| US-20210198288-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | VenatoRx Pharmaceuticals, Inc. | 2021-07-01 | — | — | US | disclosed |
| WO-2021108023-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | VenatoRx Pharmaceuticals, Inc. (US) | 2021-06-03 | — | — | WO | disclosed |
| EP-3802551-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | Venatorx Pharmaceuticals, Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
| CN-112469725-A | Penicillin binding protein inhibitors | 维纳拓尔斯制药公司 | 2021-03-09 | — | — | CN | disclosed |
| WO-2020204715-A1 | PRODRUG INHIBITORS | UNIVERSITEIT LEIDEN (NL) | 2020-10-08 | — | — | WO | disclosed |
| US-20200157123-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-05-21 | — | — | US | disclosed |
| CN-110959008-A | Penicillin binding protein inhibitors | 维纳拓尔斯制药公司 | 2020-04-03 | — | — | CN | disclosed |
| EP-0071395-A1 | Beta-lactam antibacterial agents | BEECHAM GROUP PLC (GB) | 1983-02-09 | — | — | EP | disclosed |
| US-4337197-A | BACTERICIDES | E. R. SQUIBB & SONS, INC. (US) | 1982-06-29 | — | — | US | disclosed |
| EP-0053815-A1 | 2-Oxoazetidine derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1982-06-16 | — | — | EP | disclosed |
| EP-0051381-A1 | O-sulfated beta-lactam hydroxamic acids | E.R. Squibb & Sons, Inc. (US) | 1982-05-12 | — | — | EP | disclosed |
| US-4244951-A | Bis-esters of methanediol with penicillins and penicillanic acid 1,1-dioxide | PFIZER INC. (US) | 1981-01-13 | — | — | US | disclosed |
| US-4200744-A | Substituted 7α-methoxy-7β[(2,3-dioxo-1-piperazinyl)carbonylaminophenylacetamido]cephalosporins | TOYAMA CHEMICAL COMPANY, LIMITED (JP) | 1980-04-29 | — | — | US | disclosed |
| US-4129730-A | BACTERICIDES | TOYAMA CHEMICAL CO., LTD. (JP) | 1978-12-12 | — | — | US | disclosed |
| US-4112090-A | BACTERICIDE | TOYAMA CHEMICAL CO., LTD. (JP) | 1978-09-05 | — | — | US | disclosed |
| US-4110327-A | BACTERICIDES | TOYAMA CHEMICAL CO., LTD. (JP) | 1978-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157123-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | PEPD, BPGM, EBPL | ATM 2678/4885MEN1 3629/4885KMT2A 2536/4885 |
| US-20210198288-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | PEPD, BPGM, EBPL | ATM 2678/4885MEN1 3629/4885KMT2A 2536/4885 |
| US-12173018-B2 | Penicillin-binding protein inhibitors | PEPD, BPGM, EBPL | ATM 2678/4885MEN1 3629/4885KMT2A 2536/4885 |
| US-11332485-B2 | Penicillin-binding protein inhibitors | PEPD, BPGM, EBPL | ATM 2678/4885MEN1 3629/4885KMT2A 2536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.